Raxibacumab - Emergent BioSolutions

Drug Profile

Raxibacumab - Emergent BioSolutions

Alternative Names: ABthrax; PAmAb

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Human Genome Sciences
  • Class Antibacterials; Antitoxins; Monoclonal antibodies
  • Mechanism of Action Anthrax toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anthrax

Most Recent Events

  • 03 Oct 2017 Emergent BioSolutions acquires raxibacumab from GlaxoSmithKline
  • 19 Jul 2017 Emergent BioSolutions enters into an agreement with GlaxoSmithKline to acquire raxibacumab
  • 19 Jan 2015 GlaxoSmithKline plans a phase IV immunogenicity study in Healthy volunteers in USA (NCT02339155)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top